Overview

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Subjects With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in subjects with end stage renal disease undergoing chronic hemodialysis.

Phase:

Phase 2

Details

Lead Sponsor:

Akebia Therapeutics

Treatments:

Glycine